The Global MIS Sacroiliac Joint Fusion Market was valued at nearly $330 million in 2024. This is expected to increase over the forecast period at a CAGR of 8.8%, reaching $595 million by 2031.
The full market report suite on the global market for minimally invasive sacroiliac (MIS SI) joint fusion includes market analysis complete with units sold, ASPs, and market value.
MARKET DATA INCLUDED
- Unit Sales & Average Selling Prices (ASP)
- Market Size & Growth Trends
- Procedure Numbers
- Forecasts to 2031
- Historical Data (2021-2024)
- Market Drivers & Limiters
- Competitive Landscape & Shares
- Mergers & Acquisitions
- Company Profiles & Product Portfolios
Global Sacroiliac Joint Fusion Market Trends
- Growing recognition of sacroiliac joint dysfunction as a significant source of lower back pain
- MIS techniques are increasingly preferred due to:
- Faster recovery times
- Reduced blood loss
- Lower complication rates
- Rising demand driven by both surgeon preference and patient outcomes
- Expected surge in innovation across implant design and procedural efficiency
Global Market Share Insights
1. SI-BONE - Market Leader
- First company to enter the MIS SI joint fusion market
- Flagship product: iFuse Implant System(R) (iFuse(R))
- Held ~50% market share across all regions
- Market strength driven by early-mover advantage, brand reputation, and robust clinical support
2. Medtronic - Second-Largest Competitor
- Product: ANCHOR FS(TM)
- Ranked second in North America, Western Europe, and Rest of World
- Strategic presence in mature and emerging markets with well-integrated procedural solutions
3. Globus Medical / NuVasive - Third-Largest Competitor
- Product: ZYFUSE(R)
- Ranked fourth in North America, third in Western Europe and Rest of World
- Competitive due to focus on surgical innovation and bundling with spinal systems
Research Scope Summary
- Regions
- North America (Canada, United States)
- Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru, Venezuela)
- Western Europe (Austria, Benelux, France, Germany, Italy, Portugal, Scandinavia, Spain, Switzerland, United Kingdom)
- Central & Eastern Europe (Baltic States, Bulgaria, Kazakhstan, Poland, Romania, Croatia, Czech Republic, Russia, Greece, Turkey, Hungary, Ukraine)
- Middle East (Bahrain, Iran, Israel, Kuwait, Oman, Qatar, Saudi Arabia, United Arab Emirates)
- Asia Pacific (Australia, Cambodia, China, Hong Kong, India, Indonesia, Japan, Malaysia, Myanmar, New Zealand, Pakistan, Philippines, Singapore, South Korea, Sri Lanka, Taiwan, Thailand, Vietnam)
- Africa (Algeria, Egypt, Ghana, Kenya, Libya, Morocco, Nigeria, South Africa, Sudan, Uganda)
- Base Year: 2024
- Forecast Period: 2025-2031
- Historical Data: 2021-2024
- Quantitative Data
- Procedure Numbers
- Market Size
- Market Shares
- Market Forecasts
- Market Growth Rates
- Units Sold
- Average Selling Prices
- Qualitative Data
- Market Growth Trends
- Market Limiters
- Competitive Analysis & SWOT for Top Competitors
- Mergers & Acquisitions
- Company Profiles
- Product Portfolios
- FDA Recalls
- Disruptive Technologies
- Disease Overviews
- Data Sources
- Primary Interviews with Industry Leaders
- Government Physician Data
- Regulatory Data
- Hospital Private Data
- Import & Export Data
- iData Research Internal Database